Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLCByoung Chul Cho, Patricia Lorenzini, Se-Hoon Lee et al.|New England Journal of Medicine|2024Cited by 369
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, Byoung Chul Cho et al.|Annals of Oncology|2024Cited by 81
EP.12H.02 Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 PolydamasP.J. Voon, B.C. Cho, Ju Le Tan et al.|Journal of Thoracic Oncology|2024Cited by 1